Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 10/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553193 | 0.80 | ATR (0.44) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL17204080 | 0.79 | PIK3CG (0.68) | PIK3CAPIK3CGMAPK1PIK3CD | |
| SCHEMBL17203970 | 0.76 | ALDH1A1 (0.45) | PIK3CAPIK3CGATRMAPK1ALDH1A1 | |
| SCHEMBL22553171 | 0.75 | PIK3CG (0.54) | PIK3CAPIK3CGMAPK1PIK3CD | |
| SCHEMBL17203914 | 0.75 | ALDH1A1 (0.44) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL28174453 | 0.74 | ATR (0.56) | ATRPRKDCALDH1A1TLR8 | |
| SCHEMBL21266719 | 0.72 | ALDH1A1 (0.51) | PIK3CAPIK3CGFGFR1FGFR2FGFR3 | |
| SCHEMBL17204254 | 0.71 | PIK3CG (0.54) | PIK3CAPIK3CGATRPRKDCPIK3CD | |
| SCHEMBL17204032 | 0.70 | ATR (0.52) | ATRPRKDCALDH1A1TLR8 | |
| SCHEMBL17203644 | 0.70 | ATR (0.44) | ATRPRKDCMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458979-B | Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | 诺华股份有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| EP-3134397-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015162459-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CA 27/4885PIK3CG 18/4885FGFR1 2806/4885 |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CA 27/4885PIK3CG 18/4885FGFR1 2806/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | PIK3CA 27/4885PIK3CG 18/4885FGFR1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.